Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Namenda shows benefit in behavioral disturbances associated with AD
March 22nd, 2004
Forest Laboratories, Inc., (FRX) announced the presentation of new data on behavioral outcomes from the first clinical trial evaluating the treatment of patients with moderate-to-severe Alzheimer disease with a combination of two available Alzheimer drugs: Namenda (memantine HCl) and donepezil. The results from the behavioral analysis demonstrate that treatment with Namenda and donepezil is associated with improvement in behaviors such as agitation, irritability, and appetite changes in patients with moderate-to-severe Alzheimer disease compared to baseline, while patients treated with donepezil and placebo declined relative to their baseline status. ...
Source: Health & Medicine Week (2004-03-22)
|
